Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Johns Hopkins scientist wins $2.5M NIH Director's Pioneer Award

A Johns Hopkins scientist who proposes to design and create an all-new series of novel drugs is one of 17 winners of a special grant known as a Director's Pioneer Award from the National Institutes of Health.

27 Jul 2010

Renhuang awarded AAA(1) rating

Renhuang Pharmaceuticals, Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced that the Company was recently awarded an AAA(1) rating by Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce.

23 Jul 2010

Advanced Life Sciences enters debt for equity exchange agreement with CEO

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has entered into a debt for equity exchange agreement with its chairman and CEO Michael T. Flavin, Ph.D.

23 Jul 2010

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis. The researchers will focus on antibiotic-resistant staphylococcus aureus (MRSA) infections and widespread viral infections of the skin, both of which are more prevalent among atopic dermatitis patients.

23 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

Sinobiopharma, Xianfeng enter agreement to manufacture, co-market Clindamycin and L-alanyl-L-glutamine

Sinobiopharma, Inc. is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.

21 Jul 2010

Natural, needle-free vaccination against malaria

If mice are administered an antibiotic for three days and are simultaneously infected with malaria, no parasites appear in the blood and life-threatening disease is averted. In addition, the animals treated in this manner also develop robust, long-term immunity against subsequent infections. This discovery was made by the team headed by Dr. Steffen Borrmann from the Department of Infectious Diseases at Heidelberg University Hospital in cooperation with Dr. Kai Matuschewski of the Max Planck Institute for Infection Biology in Berlin. The scientists think that safe and affordable prophylaxis with antibiotics in residents of areas with high malaria transmission has the potential to be used as a natural "needle-free" vaccination against malaria.

21 Jul 2010

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

19 Jul 2010

WPI researchers measure molecular forces that enable cranberry juice to fight off urinary tract infections

Revealing the science behind the homespun advice, a team of researchers at Worcester Polytechnic Institute (WPI) has identified and measured the molecular forces that enable cranberry juice to fight off urinary tract infections in people.

16 Jul 2010

Lyophilized rPA anthrax vaccine more immunogenic than liquid formulation: Study

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogenic than a liquid formulation of rPA vaccine and produced a robust response with only 2 doses.

16 Jul 2010

First-of-its-kind patient, healthcare provider support program for management of HE

Concentric Pharma Advertising, an independent healthcare advertising and marketing agency, announces the creation of Salix Pharmaceuticals' Hepatic Encephalopathy Living Program. H.E.L.P. launched May 24, 2010, and coincides with the launch of Xifaxan550 (rifaximin) for the management of patients 18 or older at risk for overt hepatic encephalopathy recurrence.

16 Jul 2010

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2010.

16 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

Insight into inner functional mechanisms of new bacterial infection target

In any battle, sizing up one's opponent is a critical first step. For researchers fighting a bacterial infection, that means assessing every nook and cranny of the malicious microorganism and identifying which ones to attack.

14 Jul 2010

TheraDoc clinical surveillance system helps clinicians reduce catheter-related infections: Study

Hospira, Inc., a leading provider of clinical information and medication delivery technologies, today announced a study showing how the TheraDoc clinical surveillance system helped clinicians at Memorial Hospital Miramar reduce catheter-related infections, which correlated with an increase in infection-control interventions.

14 Jul 2010

Life-or-death 'cell competition' process in mammalian tissue identified

A landmark study by Florida State University biologists, in collaboration with scientists in Britain, is the first to identify a life-or-death "cell competition" process in mammalian tissue that suppresses cancer by causing cancerous cells to kill themselves.

14 Jul 2010

Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers

Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has submitted a Special Protocol Assessment (SPA) for a proposed phase 3 clinical trial to support the U.S. approval of Cogenzia™: Innocoll's topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers.

13 Jul 2010

Palex to distribute MDI's Detect-Ready MRSA assay in Spain

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Palex Medical S.A., one of Spain's leading distributors of medical device and diagnostic products to hospitals, today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready™ MRSA assay in Spain.

13 Jul 2010

Hospitals adopt advanced computer technology to prevent HAIs

Hospitals that adopt advanced computer technology to identify healthcare-associated infections are more likely to have implemented best practices to prevent such infections, according to research presented today at the 37th Annual Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology.

13 Jul 2010

Renhuang signs Acquisition Agreement with Forest Bureau

Renhuang Pharmaceuticals, Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced that on July 8, 2010, the Company signed an Acquisition Agreement with Yichun Red Star Forest Bureau of Heilongjiang Province for indefinite exclusive access to 100,000 acres of wild Siberian Ginseng in Heilongjiang Province.

9 Jul 2010

Antibiotic News and Research

Further Reading

Johns Hopkins scientist wins $2.5M NIH Director's Pioneer Award

Renhuang awarded AAA(1) rating

Advanced Life Sciences enters debt for equity exchange agreement with CEO

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

Sinobiopharma, Xianfeng enter agreement to manufacture, co-market Clindamycin and L-alanyl-L-glutamine

Natural, needle-free vaccination against malaria

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

WPI researchers measure molecular forces that enable cranberry juice to fight off urinary tract infections

Lyophilized rPA anthrax vaccine more immunogenic than liquid formulation: Study

First-of-its-kind patient, healthcare provider support program for management of HE

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

Insight into inner functional mechanisms of new bacterial infection target

TheraDoc clinical surveillance system helps clinicians reduce catheter-related infections: Study

Life-or-death 'cell competition' process in mammalian tissue identified

Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers

Palex to distribute MDI's Detect-Ready MRSA assay in Spain

Hospitals adopt advanced computer technology to prevent HAIs

Renhuang signs Acquisition Agreement with Forest Bureau

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News